ARDX
Ardelyx, Inc.
ARDX's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ARDX overall, supported by stronger fundamentals and lower modeled downside.
ARDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARDX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARDX PE Valuation
ARDX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 253x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ARDX to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ARDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.01 | — |
| Q3 2026 | -$0.23 | +$0.01 |
| Q2 2026 | -$0.23 | +$0.01 |
| Q1 2026 | -$0.24 | -$0.01 |
| Q4 2025 | -$0.26 | -$0.09 |
| Q3 2025 | -$0.24 | +$0.06 |
| Q2 2025 | -$0.24 | +$0.03 |
| Q1 2025 | -$0.23 | +$0.05 |
| Q4 2024 | -$0.17 | +$0.13 |
ARDX is still losing money, but far less than before: $0.23 per share over the past year, against $1.13 at its worst in mid-2022.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARDX on earnings quality, reporting a profit while its opponent remains loss making.
ARDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $127.7M | +16% |
| Q2 2026 | $120.9M | +24% |
| Q1 2026 | $94.5M | +27% |
| Q4 2025 | $125.2M | +7.8% |
| Q3 2025 | $110.3M | +12% |
| Q2 2025 | $97.7M | +33% |
| Q1 2025 | $74.1M | +61% |
| Q4 2024 | $116.1M | +238% |
ARDX's revenue has grown year over year for 11 quarters in a row: $128M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.1% | -1.1 points |
| Q2 2026 | -10% | +4.5 points |
| Q1 2026 | -35% | +14 points |
| Q4 2025 | 4.1% | -2.9 points |
| Q3 2025 | 4.2% | +2 points |
| Q2 2025 | -15% | +3.9 points |
| Q1 2025 | -49% | +4.6 points |
| Q4 2024 | 7% | +88 points |
ARDX's operating margin was 3.1% last quarter, down 1.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ARDX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ARDX on profitability, with a higher operating margin.
ARDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +939% |
| Q2 2026 | -$6.4M | +$19.6M |
| Q1 2026 | -$32.3M | +$6.5M |
| Q4 2025 | $20.6M | +123% |
| Q3 2025 | $209K | -43% |
| Q2 2025 | -$26M | -$6.5M |
| Q1 2025 | -$38.8M | -$2.9M |
| Q4 2024 | $9.2M | +$18M |
ARDX has burned cash in most quarters: −$16M over the past year, against −$55M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ARDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.9M shares |
| 1 year | +3.3% | +8.1M shares |
| 3 years | +9.7% | +22.1M shares |
| 5 years | -30% | -108M shares |
ARDX has 250M diluted shares, up 3.3% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ARDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARDX Net Leverage
ARDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 9.8 | Oversold |
ARDX's weekly RSI is 30 (neutral) and its Stochastic is 10 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARDX PE vs Healthcare Sector
ARDX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.15 | 1% below |
| 20 week MA | $3.88 | 20% below |
| 50 week MA | $5.32 | 41% below |
| 100 week MA | $5.17 | 40% below |
| 200 week MA | $5.30 | 41% below |
ARDX is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ARDX on trend strength, trading above more of its moving averages.
ARDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.86 | $1.72 | -7.5% |
| 2021 | $1.72 | $1.18 | -31% |
| 2022 | $1.18 | $2.41 | +104% |
| 2023 | $2.41 | $6.20 | +157% |
| 2024 | $6.20 | $5.21 | -16% |
| 2025 | $5.21 | $5.74 | +10% |
| 2026 YTD | $5.74 | $3.12 | -46% |
ARDX has finished lower in three of the last six years. It's down 46% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ARDX on returns for 2026, with the stronger performance.